

KMAP GENERAL BULLETIN 21011

**UPDATED - New COVID ICD-10
Diagnosis Codes and PCS Procedure
Codes Effective January 1, 2021**

Effective with dates of service January 1, 2021, newly created International Classification of Diseases (ICD)-10-Clinical Modification (CM) diagnosis codes and ICD-10 Procedural Classification System (PCS) related to COVID-19 will be covered. These new codes will identify conditions resulting from COVID-19. Claims will continue to be exempt from copay when using the Centers for Medicare and Medicaid Services (CMS) approved coding guidelines and diagnosis combinations.

ICD-10 Diagnosis Codes:

Z11.52	Encounter for screening for COVID-19
Z20.822	Contact with and suspected exposure to COVID-19
Z86.16	Personal history of COVID-19
M35.81	Multisystem inflammatory syndrome
M35.89	Other specified systemic involvement of connective tissue
J12.82	Pneumonia due to coronavirus disease 2019

ICD-10 PCS Procedure Codes:

XW013H6	Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013K6	Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013S6	Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013T6	Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013U6	Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW023S6	Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6

KMAP
[Kansas Medical Assistance Program](#)

- [Bulletins](#)
- [Manuals](#)
- [Forms](#)

Customer Service

- 1-800-933-6593
- 7:30 a.m. - 5:30 p.m.
Monday - Friday



**UPDATED - New COVID ICD-10
Diagnosis Codes and PCS Procedure
Codes Effective January 1, 2021
continued**

ICD-10 PCS Procedure Codes continued:

XW023T6	Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
XW023U6	Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6
XW033E6	Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033F6	Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033G6	Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033H6	Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033L6	Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW043E6	Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043F6	Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043G6	Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043H6	Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043L6	Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
XW0DXM6	Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6

KMAP

[Kansas Medical Assistance Program](#)

- [Bulletins](#)
- [Manuals](#)
- [Forms](#)

Customer Service

- 1-800-933-6593
- 7:30 a.m. - 5:30 p.m.
Monday - Friday



**UPDATED - New COVID ICD-10
Diagnosis Codes and PCS Procedure
Codes Effective January 1, 2021
continued**

ICD-10 PCS Procedure Codes continued:

XW0G7M6	Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6
XW0H7M6	Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6

Kansas Medicaid issued guidance for billing testing and treatment of COVID-19 in [General Bulletin 20041](#).

Note: The effective date of the policy is January 1, 2021. The implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP Bulletins page documents the MCO system status for policy implementation and any associated reprocessing completion dates, once the policy is implemented.

KMAP

[Kansas Medical Assistance Program](#)

- [Bulletins](#)
- [Manuals](#)
- [Forms](#)

Customer Service

- 1-800-933-6593
- 7:30 a.m. - 5:30 p.m.
Monday - Friday